South Africa: A new phase 2b clinical trial has found that Bacille Calmette–Guérin (BCG) revaccination does not offer protection against sustained Mycobacterium tuberculosis (TB) infection in adolescents. The study, conducted by Dr. Alexander C. Schmidt and colleagues from the Gates Medical Research Institute, was published in the New England Journal of Medicine and aimed to assess whether BCG revaccination could reduce the risk of sustained TB infection in a population previously testing negative for TB and HIV .

This latest investigation was prompted by earlier findings suggesting that while BCG revaccination may not prevent primary TB infection, it could reduce the risk of persistent infections. To further explore this potential benefit, researchers carried out a double-blind

See Full Page